Menu

Report Library

All Reports

Biomedtracker Q2 2018 Outlook Report

April 04, 2018

In this report, we cover catalysts from 21 drugs expected to occur in Q2 2018. For each drug, the likelihood of Phase/PDUFA review success and overall Likelihood of Approval (LOA) given their particular phase, drug class, and disease group are provided. The results of the catalysts highlighted in our Early 2018 Outlook Report can be found on Page 4. At the end of this report, we have included a list of Large Impact catalysts through Q2 2018.

For the full report, please download the PDF version at the top of this page. Additionally, the catalyst list is provided in Excel by downloading the supplemental material at the top of this page.

Interested in medical devices? Our sister product Meddevicetracker has published a concurrent report on 9 device catalysts expected to occur in Q2 2018. This report can be downloaded for free here.


Like our report? Have any questions or feedback? Please let us know at askanalyst@sagientresearch.com.

For our disclosures, please read the Biomedtracker Research Standards.
Indications Covered: Amyloidosis
Anemia Due to Chronic Kidney Disease, Dialysis-Independent
Breast Cancer
Chronic Lymphocytic Leukemia (CLL)/Small Cell Lymphocytic Lymphoma (SLL) - NHL
Diabetes Mellitus, Type II
Dravet Syndrome (Epilepsy)
Graft vs. Host Disease (GVHD) - Treatment
Hospital Acquired (Nosocomial) Pneumonia (HAP) (Antibacterial)
Lennox-Gastaut Syndrome (LGS; Epilepsy)
Melanoma
Migraine and Other Headaches
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Phenylketonuria (PKU)
Postsurgical Pain
Renal Cell Cancer (RCC)
Rheumatoid Arthritis (RA)
Septicemia or Bacteremia (Antibacterial, including Endocarditis)
Thrombocytopenia
Urinary Tract and Reproductive Tract Infections (Antibacterial)

 Additional Resources: